Bluejay Diagnostics, Inc.
BJDX
Last
$0.82
Day
+1.0%
1y
-93.8%
5y
-100.0%
52w
-95.1%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-0626d
EMA 21
0.87
EMA 50
1.04
EMA 200
14.74
20d high
-20.8%
5y high
-100.0%
5y range
0th
Positions held
Your positionsBJDX isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-27
Hold
avoid
Signal
Strong Sell
Target
$0.93
Stop
$0.72
Stop distance
12.6%
Target vs last
+12.9%
Fundamentals
| Market cap | $3.64M | Enterprise value | -$5.87M | Trailing P/E | — | Forward P/E | -2.55 |
| PEG | — | Price / book | 0.17 | Beta | 0.89 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -98.9% | ROA | -51.1% | Debt / equity | 0.01 |
| Current ratio | 4.64 | Free cash flow | -$3.55M | Analyst recommendation | none | Mean target | — |
| 52w high | $16.68 | 52w low | $0.76 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$2.3M | -$1.9M | -$1.4M | -$1.6M | -$2.0M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$2.3M | -$1.9M | -$1.5M | -$1.6M | -$2.0M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.2M | — |
| Op margin | — | — | — | -3741.5% | — |
| Net income | -$6.8M | -$7.7M | -$10.0M | -$9.3M | — |
| Gross margin | — | — | — | 19.6% | — |
| Gross profit | — | — | $0.0M | $0.0M | $0.0M |
| Operating income | -$7.0M | -$7.2M | -$10.3M | -$9.3M | — |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-06 · Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients
2026-09-08 · Bluejay Diagnostics Federal Healthcare Partnership Builds Commercial Pathway Ahead of FDA Clearance
2026-09-08 · BC-Most Active Stocks
2026-08-05 · BC-Most Active Stocks
2026-08-05 · Top Premarket Gainers
2026-07-21 · Bluejay Diagnostics Completes Enrollment in SYMON-II Clinical Validation Study
Price (daily)
Full chart · RSI · MACD · patternsBJDX · daily-10.6% over 14 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin